Genetic and clinical markers for predicting treatment responsiveness in rheumatoid arthritis

Front Med. 2019 Aug;13(4):411-419. doi: 10.1007/s11684-018-0659-3. Epub 2019 Jan 12.

Abstract

Although many drugs and therapeutic strategies have been developed for rheumatoid arthritis (RA) treatment, numerous patients with RA fail to respond to currently available agents. In this review, we provide an overview of the complexity of this autoimmune disease by showing the rapidly increasing number of genes associated with RA.We then systematically review various factors that have a predictive value (predictors) for the response to different drugs in RA treatment, especially recent advances. These predictors include but are certainly not limited to genetic variations, clinical factors, and demographic factors. However, no clinical application is currently available. This review also describes the challenges in treating patients with RA and the need for personalized medicine. At the end of this review, we discuss possible strategies to enhance the prediction of drug responsiveness in patients with RA.

Keywords: clinical markers; gene; rheumatoid arthritis; therapy.

Publication types

  • Review

MeSH terms

  • Antirheumatic Agents / therapeutic use*
  • Arthritis, Rheumatoid / drug therapy*
  • Arthritis, Rheumatoid / genetics*
  • Biomarkers*
  • Drug Resistance
  • Gene Expression
  • Genotype
  • Humans
  • Precision Medicine*
  • Tumor Necrosis Factor-alpha / genetics

Substances

  • Antirheumatic Agents
  • Biomarkers
  • Tumor Necrosis Factor-alpha